MoonLake Immunotherapeutics
NASDAQ:MLTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
MoonLake Immunotherapeutics
NASDAQ:MLTX
|
CH |
|
Leonteq AG
SIX:LEON
|
CH |
|
DPM Metals Inc
F:DPU0
|
CA |
|
A
|
Avillion Bhd
KLSE:AVI
|
MY |
|
Zoominfo Technologies Inc
F:ZOM
|
US |
|
B
|
Bank of America Corp
SIX:BAC
|
US |
Intrinsic Value
Is MLTX undervalued or overvalued?
See the intrinsic value estimate for MoonLake Immunotherapeutics and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What MoonLake Immunotherapeutics Does
MoonLake Immunotherapeutics is a clinical-stage biotechnology company that develops medicines for inflammatory and autoimmune diseases. Its main drug candidate is sonelokimab, a lab-made antibody fragment designed to block a pathway involved in conditions such as psoriasis and hidradenitis suppurativa. The company is still focused on testing and advancing this drug rather than selling a broad portfolio of products.
- Headquarters
- Switzerland CH
- Employees
- 130
- IPO date
- Oct 20, 2020
Earnings Waterfall
MoonLake Immunotherapeutics
The intrinsic value for MoonLake Immunotherapeutics (MLTX) under the Base Case is hidden USD.
Compared with the current market price of 12.2 USD, the stock appears hidden.